AtriCure (ATRC) EBIT (2010 - 2026)

AtriCure (ATRC) has reported EBIT for 17 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 256.09% year-over-year to $9.7 million in Q2 2026; TTM through Jun 2026 was $12.9 million, a 137.83% increase from a year earlier, with the FY2025 full-year figure at -$9.4 million, up 76.39% from the prior year.
• EBIT was $9.7 million for Q2 2026 at AtriCure, up from $526000.0 in the prior quarter.
• Over five years, EBIT peaked at $9.7 million in Q2 2026 and troughed at -$14.5 million in Q4 2024.
• A 5-year average of -$6.0 million and a median of -$6.7 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT sank 110.87% in 2022 and jumped 256.09% in 2026, its largest moves.
• Over 5 years, EBIT stood at -$4.1 million in 2022, then plunged by 109.57% to -$8.7 million in 2023, then tumbled by 67.55% to -$14.5 million in 2024, then soared by 117.15% to $2.5 million in 2025, then soared by 288.0% to $9.7 million in 2026.
• The last three EBIT figures came in at $9.7 million (Q2 2026), $526000.0 (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.